ONCT - Oncternal Therapeutics soars after presenting data at ASH

Oncternal Therapeutics (ONCT) announces updated interim clinical data from the ongoing Phase 1/2 CIRLL clinical trial. "The interim data from the combination of cirmtuzumab and ibrutinib are quite promising in relapsed/refractory (r/r) MCL, with an impressive 87% best ORR that has improved over time. The time to response, depth and durability of responses make cirmtuzumab a compelling candidate for further development," say an investigator in the trial. As of the data cut-off date of October 30, 15 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of this clinical trial were evaluable for efficacy and saw an improved objective response rate of 87%.ONCT +26.69% premarket to $3.37.Source: Press Release

For further details see:

Oncternal Therapeutics soars after presenting data at ASH